165 related articles for article (PubMed ID: 28749644)
21. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of human papillomavirus vaccination in Germany.
Damm O; Horn J; Mikolajczyk RT; Kretzschmar MEE; Kaufmann AM; Deleré Y; Ultsch B; Wichmann O; Krämer A; Greiner W
Cost Eff Resour Alloc; 2017; 15():18. PubMed ID: 28878573
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
26. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
[TBL] [Abstract][Full Text] [Related]
27. Age-based programs for vaccination against HPV.
Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
[TBL] [Abstract][Full Text] [Related]
28. Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model.
Kawai K; de Araujo GT; Fonseca M; Pillsbury M; Singhal PK
BMC Infect Dis; 2012 Oct; 12():250. PubMed ID: 23046886
[TBL] [Abstract][Full Text] [Related]
29. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
30. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
Szucs TD; Largeron N; Dedes KJ; Rafia R; Bénard S
Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014
[TBL] [Abstract][Full Text] [Related]
32. Introduction of a National HPV vaccination program into Bhutan.
Dorji T; Tshomo U; Phuntsho S; Tamang TD; Tshokey T; Baussano I; Franceschi S; Clifford G
Vaccine; 2015 Jul; 33(31):3726-30. PubMed ID: 26057136
[TBL] [Abstract][Full Text] [Related]
33. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
Sharma M; Sy S; Kim JJ
BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model.
Dasbach EJ; Largeron N; Elbasha EH
Expert Rev Pharmacoecon Outcomes Res; 2008 Oct; 8(5):491-500. PubMed ID: 20528334
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.
Mennini FS; Bonanni P; Bianic F; de Waure C; Baio G; Plazzotta G; Uhart M; Rinaldi A; Largeron N
Cost Eff Resour Alloc; 2017; 15():11. PubMed ID: 28701899
[TBL] [Abstract][Full Text] [Related]
36. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
37. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
[TBL] [Abstract][Full Text] [Related]
38. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France.
Majed L; Bresse X; El Mouaddin N; Schmidt A; Daniels VJ; Pavelyev A; Levy-Bachelot L; Elbasha E
Vaccine; 2021 Jan; 39(2):438-446. PubMed ID: 33261895
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
40. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
Ezat SW; Aljunid S
Asian Pac J Cancer Prev; 2010; 11(4):943-51. PubMed ID: 21133606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
